Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Accumulated Expenses for 18 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.

• Quarterly Other Accumulated Expenses rose 15.25% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 15.25% YoY) and the FY2025 annual result came in at $1.2 billion, up 15.88% from the prior year.
• Other Accumulated Expenses fell to $1.1 billion in Q1 2026 per TEVA's latest filing, from $1.2 billion in the prior quarter.
• Over the last five years, Other Accumulated Expenses for TEVA reached as high as $1.2 billion in Q3 2024 and fell as low as $900.0 million in Q1 2022.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2023 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses grew 22.75% — and 2025, when it declined 21.07%.
• Year by year, Other Accumulated Expenses stood at $1.0 billion in 2022, then increased by 3.88% to $1.0 billion in 2023, then declined by 2.3% to $1.0 billion in 2024, then advanced by 15.88% to $1.2 billion in 2025, then slipped by 6.01% to $1.1 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $1.1 billion, $1.2 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.